SLU-PP-332
Research OnlyAlso known as: ERR agonist 332, Exercise mimetic compound
A small molecule ERR (Estrogen-Related Receptor) agonist developed at Saint Louis University. Preclinical studies suggest exercise-mimetic properties, but no human data exists. Represents early-stage research into pharmacologically activating exercise pathways.
Research Statistics
Very early-stage ERR/PPAR pan-agonist; single research group (Bhatt lab, USC). Only mouse preclinical data published. No human trials. ERRalpha/delta agonism as exercise-mimetic mechanism is plausible based on known ERR biology but unvalidated in humans.
Research Dossier
Overview
What is SLU-PP-332 and what does the research say?
Mechanism of Action
The proposed mechanisms of SLU-PP-332 are based entirely on animal and in vitro studies. No human mechanistic data exists, and this compound has never been tested in humans.
How It Works (Simplified)
SLU-PP-332 aims to activate “exercise pathways” pharmacologically by targeting ERR receptors:
Binds to ERRalpha and ERRgamma receptors, triggering transcription of metabolic genes normally activated by exercise.
Promotes PGC-1alpha coactivation, signaling cells to build more mitochondria and enhance energy production capacity.
Upregulates genes for fatty acid oxidation and oxidative phosphorylation, enhancing aerobic energy pathways.
In mice, these changes translated to improved treadmill endurance and reduced muscle fatigue markers.
Scientific Pathways
ERR-PGC-1alpha Axis (Mitochondrial Biogenesis)
SLU-PP-332 → ERRalpha/ERRgamma Activation → PGC-1alpha Coactivation
↓
Mitochondrial biogenesis genes
Fatty acid oxidation genes
Oxidative phosphorylation genesExercise Mimetic Pathway (Metabolic Enhancement)
SLU-PP-332 → ERR Target Genes → OXPHOS/FAO Upregulation → Enhanced Aerobic CapacityKey Research: Kim SH et al. (Saint Louis University, 2023) demonstrated ERR-mediated endurance enhancement in mouse models. PMID:37399371
Important Limitations
- Mouse-only data - SLU-PP-332 has never been tested in humans
- Single research group - Most data originates from one laboratory
- Pharmacokinetics unknown - No data on absorption, metabolism, or distribution in humans
- Long-term safety unknown - Chronic ERR activation effects are uncharacterized
- Research compound only - Not manufactured to pharmaceutical standards
- Translation uncertain - Mouse exercise physiology differs substantially from humans
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on mouse studies: ERR target gene activation may begin within days. Changes in oxidative gene expression observed in animal models. No human timeline data available.
Mouse studies suggest mitochondrial biogenesis markers increase over this timeframe. PGC-1alpha pathway activation observed. Human response completely unknown.
In mouse endurance studies, functional improvements in running capacity observed by 4-8 weeks. Translation to human physiology is entirely speculative.
Long-term effects unknown. Chronic ERR activation has not been studied in any species for extended periods. Safety of prolonged use is completely uncharacterized.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate SLU-PP-332 product quality
Good Signs (5 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining SLU-PP-332 with other peptides. Based on published research and mechanistic considerations.
Metformin
CompatibleDifferent mechanisms (metformin primarily affects hepatic gluconeogenesis and AMPK, SLU-PP-332 targets ERR in muscle). Theoretical complementary effects but no combined studies.
BPC-157
CompatibleNon-overlapping mechanisms. BPC-157 focuses on tissue repair while SLU-PP-332 targets metabolic pathways. No known contraindications.
TB-500
CompatibleNon-overlapping mechanisms. TB-500 focuses on tissue repair and cell migration while SLU-PP-332 targets ERR-mediated metabolic pathways. No interaction data available.
Aicar
CautionBoth target exercise-mimetic pathways (AICAR via AMPK, SLU-PP-332 via ERR). Combined activation of these parallel pathways has not been studied. Theoretical synergy but unknown safety profile.
Sr9009
CautionBoth target metabolic enhancement through nuclear receptor modulation (SR9009 via REV-ERB, SLU-PP-332 via ERR). No interaction data available. Exercise caution with combined metabolic modulators.
Gw501516
AvoidGW501516 development was halted due to cancer concerns in animal studies. Combining with another metabolic modulator increases theoretical risk. Neither compound has human safety data.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare SLU-PP-332
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium, NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111, Oral Amycretin, Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191, hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833, NN9838, ZP8396
A long-acting amylin analog developed by Novo Nordisk for weight management. Currently in Phase 3 trials as CagriSema (combination with semaglutide). Phase 2 data shows up to 22-25% weight loss when combined with semaglutide, potentially exceeding tirzepatide efficacy.
CagriSema
Cagrilintide-Semaglutide, NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. Phase 1b results showed 18.8% placebo-adjusted weight loss at 24 weeks, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.